The Zhitong Finance App learned that CRO concept stocks generally rose today. As of press release, Gloria Ying (06821) rose 6.57% to HK$129.7; Zhaoyan Pharmaceutical (06127) rose 6.5% to HK$21.96; Kanglong Chemical (03759) rose 6.04% to HK$23.54; and Pharmaceuticals (02359) rose 5.41% to HK$159.8.
According to news, in the first half of this year, the domestic innovative drug BD reached a new high in the same period, compounded by a marked recovery in overseas biomedical financing. A number of forward-looking indicators confirm the simultaneous improvement in domestic and foreign demand. On the evening of July 13, Kanglong Chemical disclosed its semi-annual performance forecast. The company's new orders increased by more than 30% year on year; among them, new orders for laboratory services increased by more than 20% year on year, and new orders for small molecule CDMO services increased by more than 50% year on year. It is worth mentioning that due to active research and development of new drugs, the price of experimental monkeys has risen again. According to reports, the current value of crab-eating monkeys has exceeded 200,000 yuan.
According to the Huaxin Securities Research Report, since the beginning of June, the CXO sector has taken the lead in rebounding from innovative drugs, supported by performance and orders. From June 8 to July 10, the CRO index rebounded 21.72%. Looking ahead to the second half of the year, the growth in innovative drug financing will continue to support the continuation of CXO boom. Currently, leading CRO company Yao Ming Kangde predicts PE of 17.58X and Gloria Ying of 33.19X in 2027. As the interim results approach, the order trend for the 2nd quarter gradually becomes clear, and the CXO rebound is expected to be supported by performance.